stockrowIterum Therapeutics PLC
ITRMF Healthcare Biotechnology
- Revenue
- +110.8%
- EPS
- +33.3%
- Free cash flow
- −179.2%
Quarter to September 2025, against a year earlier
Follow ITRMF
Alert me
Iterum Therapeutics PLC (ITRMF) EV/Sales
As of 16 October 2026, Iterum Therapeutics PLC (ITRMF) trades at a EV/Sales of 24.4×. Over the past ten years it has ranged from −64.6× (December 2022) to 468× (June 2021); the current reading is higher than 41% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2019 | 103× | — |
| FY2018 | −30.7× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2025 | 57.7× | (30.83%) |
| Mar 2019 | 83.4× | — |
| Dec 2018 | −30.7× | — |
| Sep 2018 | 1.7× | — |
| 3 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| GOVX GeoVax Labs Inc. compare | −0.3× |
| CARM Carisma Therapeutics Inc. compare | 0.0× |
| GNPX GENPREX compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| OGEN Oragenics, Inc. compare | 0.7× |
| ITRMF Iterum Therapeutics PLC | 24.4× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)